Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Strikes $500m Deal For GSK Cephalosporins

Deal To Acquire Cephalosporins Business Reinforces Position In Antibiotics

Executive Summary

Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.

You may also be interested in...



AMR Industry Alliance Publishes Manufacturing Standard

The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.

AMR Industry Alliance Publishes Manufacturing Standard

The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.

Sandoz And Ares Extend AMR Collaboration Ahead Of Next Phase

With plans to enable genomic surveillance for antimicrobial resistant pathogens using Ares’ next-generation sequencing and bioinformatics technologies, the OpGen subsidiary and Sandoz have shaken hands on an extension to their initial master services agreement.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel